Targeting hybrid histidine kinase for broad spectrum antifungal therapy

靶向混合组氨酸激酶进行广谱抗真菌治疗

• 批准号: 7936212
• 负责人: BRUCE Steven KLEIN
• 金额: $ 49.56万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-26 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7936212
• 关键词: 3-Dimensional; Address; Agriculture; Americas; Animals; Antibiotic Resistance; Antifungal Agents; Antifungal Therapy; Area; Aspergillus; Aspergillus fumigatus; Azole resistance; Binding; Biological Assay; Biological Markers; Biology; Candida; Candida albicans; Caspofungin; Cells; Cessation of life; Chemicals; Chemistry; Communicable Diseases; Congresses; Data; Databases; Development; Disease; Docking; Drug Delivery Systems; Evaluation; Food; Galactosidase; Goals; Grant; Growth; Hand; Human; Human Genome; Hybrids; In Vitro; Individual; Industrial fungicide; Infection; Institution; Lead; Libraries; Malignant Neoplasms; Mammalian Cell; Microbe; Modeling; Molds; Molecular; Mus; Mycoses; Pathway interactions; Patients; Pharmaceutical Preparations; Pharmacologic Substance; Pharmacotherapy; Pharmacy facility; Phosphotransferases; Plants; Pneumonia; Prevalence; Public Health; Reaction; Reporter; Research Infrastructure; Research Personnel; Resistance; Role; Running; Saccharomyces cerevisiae; Sepsis; Signal Pathway; Signal Transduction; Societies; Stress; Structure; System; Temperature; Testing; Toxic effect; Toxicity Tests; United States; Validation; Virulence; Work; Yeasts; antimicrobial; bacterial resistance; base; chemical genetics; cross reactivity; cytotoxic; design; dimorphism; drug discovery; fludioxonil; fungus; glucan synthase; high throughput screening; in vitro Assay; in vitro activity; in vivo; inhibitor/antagonist; insight; killings; mammalian genome; mortality; novel; pathogen; pathogenic bacteria; pharmacophore; protein-histidine kinase; public health relevance; research and development; response; sensor; small molecule; small molecule libraries; three dimensional structure; virtual

DESCRIPTION (provided by applicant): This challenge grant addresses the broad challenge area (03) "Biomarker Discovery and Validation". The challenge topic is 03-AI-101, entitled "Identification, characterization and evaluation of novel pathogen or host targets that may lead to the development of antimicrobials with broad-spectrum activity." The title of the proposal is: Targeting hybrid histidine kinase for broad-spectrum antifungal therapy. Despite the growing prevalence of severe fungal infections, we have a paucity of anti-fungal drugs, most of them are fraught with toxicity due to cross-reactivity with shared mammalian host targets, and only one new class of anti-fungal has been developed in the last decade. This proposal is designed to capitalize on a recent path-breaking discovery that a hybrid histidine kinase regulates global control of dimorphism and virulence in fungi. We hypothesize that hybrid histidine kinase represents an ideal target for the development of anti- fungal drugs to treat patients. This new target offers many features that the field has been seeking for development of broad-spectrum anti-fungal drugs, since it is highly conserved throughout the fungal kingdom and is not present in the human genome. We provide strong preliminary data supporting the concept and feasibility of this novel drug target. We have in place a strong drug discovery infrastructure for developing anti-fungal drugs, with campus leaders who are co-investigators on this grant, offering expertise in key areas and facility support, ranging from fungal and chemical biology, medicinal pharmacy, and drug lead optimization involving in vitro and in vivo animal studies. Our approach offers a powerful complimentary strategy that provides a cell based reporter system for identifying compounds that require the signaling pathway for their mode of action (aim 1), together with a pharmacophore 3-D model to find compounds that directly act on these targets in pathogenic fungi of divergent genera throughout the kingdom (aims 2 and 3). We expect that this work will ultimately lead to anti-fungal drugs that target multiple steps in this pathway, and are effective at treating a broad range of serious fungal infections in humans and perhaps plants. PUBLIC HEALTH RELEVANCE: The number of fungal infections has risen dramatically in the United States over the last 10 years, and has reached the top 10 in causes of annual mortality in part because of the lack of efficacious anti-fungal drugs. This proposal addresses that public health need by seeking to identify, characterize and capitalize on a novel drug target in pathogenic fungi for the development of effective new anti-fungal drugs.

描述（由申请人提供）：该挑战授权解决了广泛的挑战领域（03）“生物标志物发现和验证”。挑战主题是03-AI-101，标题为“可能导致开发具有广谱活性的抗菌剂的新型病原体或宿主靶标的鉴定、表征和评价”。“该提案的标题是：靶向杂交组氨酸激酶用于广谱抗真菌治疗。尽管严重真菌感染的患病率不断增加，但我们缺乏抗真菌药物，其中大多数药物由于与共享的哺乳动物宿主靶点的交叉反应而充满毒性，并且在过去十年中仅开发了一类新的抗真菌药物。这项建议的目的是利用最近的一个开创性的发现，一个混合组氨酸激酶调节全球控制真菌的二型性和毒力。我们假设，杂合组氨酸激酶代表了一个理想的目标，为发展抗真菌药物治疗患者。这个新靶点提供了该领域一直在寻求开发广谱抗真菌药物的许多特征，因为它在整个真菌王国中高度保守，并且不存在于人类基因组中。我们提供了强有力的初步数据支持这种新型药物靶点的概念和可行性。我们有一个强大的药物发现基础设施，用于开发抗真菌药物，与校园领导谁是共同研究者在此赠款，提供关键领域的专业知识和设施支持，从真菌和化学生物学，药用制药，药物铅优化涉及体外和体内动物研究。我们的方法提供了一个强大的互补策略，提供了一个基于细胞的报告系统，用于识别需要信号传导途径的化合物，其作用模式（目标1），以及药效团3-D模型，以找到直接作用于这些目标的化合物在病原真菌的不同属在整个王国（目标2和3）。我们预计，这项工作将最终导致针对该途径中多个步骤的抗真菌药物，并有效治疗人类和植物中广泛的严重真菌感染。 公共卫生关系：在过去的10年中，美国真菌感染的数量急剧上升，并且已经达到年度死亡原因的前10位，部分原因是缺乏有效的抗真菌药物。该提案通过寻求鉴定、表征和利用病原真菌中的新型药物靶标来开发有效的新型抗真菌药物来解决公共卫生需求。